When will I notice results from my vitamin B12 injection
Quinone reductase 2 as a promising target of melatonin therapeutic actions
Key areas of research interest include: Hypoactive Sexual Desire Models Neuroendocrine Signaling Studies Melanocortin Receptor Pharmacodynamics Dopaminergic Activation and Reward Response Central Nervous System Modulation Unlike PDE5 inhibitors that require peripheral arousal signals (like nitric oxide), PT141 has been shown in preclinical models to influence sexual motivation directly via neural circuits , making it a unique subject of CNS-focused sexual function research
Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
